Too often, recruiters are more clear on what a position will “do” rather than what it will “achieve”.Outlining tasks and responsibilities takes priority over goals and impact.But to attract top talent, you need to define and explain what success looks…
MHLW Panel Recommends Lifting Ban on Cannabis-Derived Drugs, Eyes Legal Amendment Next Spring
To read the full story
Related Article
- Japan Diet Enacts Bill to Lift Ban on Cannabis-Derived Drugs
December 8, 2023
- MHLW Set to Submit Bill to Lift Ban on Cannabis-Derived Drugs
October 11, 2023
- MHLW Moving Toward Allowing Use of Cannabis-Derived Drugs: LDP Session
September 8, 2023
- MHLW Likely to Give Up Submitting Bill to Lift Bans on Cannabis-Derived Drugs
January 13, 2023
- MHLW Panel Proposes Lifting Bans on Cannabis-Derived Drugs, Introducing Distribution Control
October 3, 2022
- MHLW Eyes Diet Submission of Bill to Amend Cannabis Control Act Next Year: Official
September 20, 2022
- MHLW Panel to Discuss Cultivation of Cannabis for Use as Pharmaceutical Ingredient
July 1, 2022
- Japan Should Accelerate Debate on Legalizing Cannabis-Derived Drugs for Refractory Epilepsies
June 27, 2022
- MHLW Announces Recommendation for Cannabis Drug Debate
June 28, 2021
- Manufacturing and Use of Cannabis-Derived Drugs Should Be Permitted: MHLW Panel
June 2, 2021
- MHLW Proposes Lifting Domestic Ban on Cannabis-Derived Drugs, Seeking “Ingredient-Based” Regulation
May 18, 2021
REGULATORY
- MHLW Generic Panel Outlines Plan to Drive Industry Revamp within Specific Time Frame
March 28, 2024
- Japan’s HIV, AIDS Cases Rebound in 2023 after COVID
March 28, 2024
- Japan Govt Launches Panel to Respond to Red Yeast Rice Issue
March 28, 2024
- Japan Approves Piasky, Beyfortus, Broader Use for Abrysvo, and Lot More
March 27, 2024
- PMDA Chief Fujiwara to Remain Skipper for Another Term
March 27, 2024
Pharmaceutical companies are giving high marks to Japan’s drug pricing reform for FY2024. According to a survey conducted by Jiho, 51% of all respondents expressed a positive opinion of the reform, saying that they were “somewhat satisfied” with it. The…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…